High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors

References

• Government of Canada. For health professionals: Flu (influenza). 2015. Available at: http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/professionals-professionnels-eng.php
   Google Scholar
• Schanzer DL, Tam TW, Langley JM, Winchester BT. Influenza-attributable deaths, Canada 1990-1999. Epidemiol Infect 2007; 135:1109-16; PMID:17306052; http://dx.doi.org/10.1017/S0950268807007923
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Estimates of deaths associated with seasonal influenza — United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62; PMID:20798667
   PubMedGoogle Scholar
• Sanofi Pasteur. FLUZONE® High-Dose Influenza Virus Vaccine Trivalent Types A and B (Splite Virion). Product monograph. Control number: 179780. Date of approval: September 9, 2015. Available at: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=93092&lang=eng
   Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Engl J Med 2014; 371:635-45; PMID:25119609; http://dx.doi.org/10.1056/NEJMoa1315727
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep 2012; 61:414-20; PMID:22672977
   PubMedGoogle Scholar
• Centers for Disease C, Prevention. Estimated influenza illnesses and hospitalizations averted by influenza vaccination - United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2013; 62:997-1000; PMID:24336131
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Influenza activity–United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 2013; 62:473-9; PMID:23760189
   PubMed Web of Science ®Google Scholar
• Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 2013; 88:101-14
   PubMedGoogle Scholar
• Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. The Lancet Infect Dis 2015; 15:1459-66; PMID:26362172; http://dx.doi.org/10.1016/S1473-3099(15)00249-2
   PubMed Web of Science ®Google Scholar
• Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine 2015; 33:734-41; PMID:25444791; http://dx.doi.org/10.1016/j.vaccine.2014.10.079
   PubMed Web of Science ®Google Scholar
• Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2006.
   Google Scholar
• Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med 2003; 22:1955-76; PMID:12802815; http://dx.doi.org/10.1002/sim.1389
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Table 326-0020 - Consumer Price Index (CPI), 2011 basket, monthly. Available at: http://www5.statcan.gc.ca/cansim/a26
   Google Scholar
• Centers for Medicare & Medicaid Services. Seasonal Influenza Vaccines Pricing. 2014. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-BDrugs/McrPartBDrugAvgSalesPrice/VaccinesPricing.html
   Google Scholar
• Ontario Ministry of Health and Long-term Care, Drug Programs and Policy and Strategy Branch. Ontario Drug Benefit Formulary/Comparative Drug Index, Edition 42. Effective September 25, 2014. Available at: https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp
   Google Scholar
• Canadian Association for Pharmacy Distribution Management (CAPDM). Guidebook on Government Drug Reimbursement Plans and Related Programs 2014.
   Google Scholar
• Canadian Institute for Health Information. Analysis in brief. Seniors' use of emergency departments in Ontario, 2004-2005 to 2008-2009. February 2010. Available at: https://secure.cihi.ca/free_products/seniors_ed_e.pdf
   Google Scholar
• Canadian Institute for Health Information. Physician services benefit rates report, Canada, 2012-2013. Available at: https://secure.cihi.ca/free_products/PSBR-2013_2014_EN_web.pdf
   Google Scholar
• Ontario Case Costing Initiative (OCCI). Costing analysis tool (CAT). 2014. Available at: https://www.occp.com/mainPage.htm
   Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Table 281-0063 - Employment and average weekly earnings including overtime (SEPH), seasonally adjusted, for all employees by industries classified using the North American Industry Classification System (NAICS), monthly (persons unless otherwise noted). 2014. Available at: http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=2810063
   Google Scholar
• Statistics Canada, Demography Division. Life tables, Canada, provinces and territories (84-537-X). 2013. Available at:http://www5.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno=84-537-X&lang=eng
   Google Scholar
• DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015; 33:4988-93; PMID:26212007; http://dx.doi.org/10.1016/j.vaccine.2015.07.006
   PubMed Web of Science ®Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10:779-87; PMID:11747057; http://dx.doi.org/10.1002/hec.635
   PubMed Web of Science ®Google Scholar